Derma Sciences, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.
The company announced in the following press release that, “DSC127, a novel angiotensin analog, has been shown to improve epithelialization, granulation, vascularization, and accelerate wound healing in a variety of normal and diabetic animal models. This finding suggests that DSC127 produces different actions at the wound site during various stages of healing. There were no safety concerns observed in the preclinical and human Phase 1 studies of DSC127. ” Read the full article.
Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company’s advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. [Source: GoogleFinance]
Company Website: http://www.dermasciences.co